No merit seen in including Paxlovid in Covid treatment ICMR



Published
Pfizer's antiviral drug Paxlovid is going cross sign --to be not included in the national treatment guidelines for Covid-19. Confirmation to this effect was recently made by the Experts from the Indian Council of Medical Research (ICMR) to the daily Economic Times who said that the apex medical authority has Not found a compelling reason to include the drug in the national treatment guidelines for Covid-19.


Get the latest medical and heath news at medicaldialogues.in
Follow us on
Twitter: https://twitter.com/medicaldialogs
Facebook: https://www.facebook.com/medicaldialogues/
Instagram: https://www.instagram.com/medicaldialogues
LinkedIn: https://www.linkedin.com/company/medical-dialogues
Website: https://medicaldialogues.in/
Category
Health
Be the first to comment